Published in Ther Clin Risk Manag on April 15, 2010
Inhibition of soluble epoxide hydrolase limits niacin-induced vasodilation in mice. J Cardiovasc Pharmacol (2012) 0.79
Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parameters. Clin Med Insights Cardiol (2011) 0.75
Prediction of coronary heart disease using risk factor categories. Circulation (1998) 48.81
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation (1989) 9.97
Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med (2009) 9.35
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med (2001) 7.69
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med (1990) 6.43
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol (1986) 6.27
Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA (1987) 5.82
Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care (2008) 3.65
Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation (1998) 3.42
Clofibrate and niacin in coronary heart disease. JAMA (1975) 3.39
Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand (1988) 2.86
Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA (1990) 2.78
Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med (2002) 2.77
Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol (1998) 2.74
High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis (1989) 2.65
Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med (2005) 2.40
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA (1990) 2.36
Safety considerations with niacin therapy. Am J Cardiol (2006) 2.30
High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial. Am J Cardiol (2000) 2.21
The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin (2006) 1.53
Atheroprotective effects of high-density lipoproteins. Annu Rev Med (2001) 1.46
Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med (1994) 1.46
Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis (2008) 1.45
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol (2008) 1.43
Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol (1998) 1.28
Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract (2008) 1.27
The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J (1998) 1.26
Validation of a questionnaire to assess niacin-induced cutaneous flushing. Curr Med Res Opin (2007) 1.22
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol (2007) 1.22
Comparison of factors associated with 30-day mortality after coronary artery bypass grafting in patients with versus without diabetes mellitus. Israeli Coronary Artery Bypass (ISCAB) Study Consortium. Am J Cardiol (1998) 1.16
Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol (2002) 1.15
Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol (2005) 1.14
Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol (2000) 1.13
Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol (2006) 1.09
Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res (1981) 1.06
Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med (2000) 1.01
Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents? Am J Cardiol (2007) 0.91
Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study. Curr Med Res Opin (2006) 0.91
Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview. Clin Ther (2009) 0.91
Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol (2003) 0.91
Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist. Clin Pharmacol Ther (2007) 0.87
Triglycerides are more important in atherosclerosis than epidemiology has suggested. Atherosclerosis (1998) 0.87
What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush? Curr Opin Lipidol (2009) 0.85
The effect of MK-0524, a prostaglandin D(2) receptor antagonist, on prostaglandin D (2)-induced nasal airway obstruction in healthy volunteers. Eur J Clin Pharmacol (2007) 0.83
Dosage, titration, and gaps in treatment with extended release niacin in clinical practice. Curr Med Res Opin (2008) 0.82
Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol Clin (2008) 0.81
Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms. J Clin Pharmacol (2009) 0.81
Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). Am Heart J (2000) 0.80
Unstable myocardial ischemia after the initiation of niacin therapy. Am J Cardiol (1991) 0.80
Does nicotinic acid (niacin) lower blood pressure? Int J Clin Pract (2008) 0.80
Extended-release niacin/lovastatin: the first combination product for dyslipidemia. Expert Rev Cardiovasc Ther (2004) 0.78
Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial. Int J Clin Pract (2008) 0.78
Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physician. Arch Intern Med (1994) 0.76
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA (2006) 9.27
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93
Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med (2007) 6.79
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet (2010) 6.23
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA (2007) 5.89
Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med (2007) 4.30
Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med (2006) 3.90
Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA (2008) 3.64
Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol (2006) 3.54
Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation (2008) 2.34
A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: the tacrolimus in combination, tacrolimus alone compared (TICTAC) trial. Circ Heart Fail (2011) 2.15
The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis. Arch Intern Med (2010) 1.98
Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease. Clin Chem (2010) 1.74
Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. Eur Heart J Cardiovasc Imaging (2014) 1.64
Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis. J Am Coll Cardiol (2009) 1.58
Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J Am Coll Cardiol (2010) 1.56
Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. Ann Intern Med (2007) 1.54
Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. Eur Heart J (2013) 1.49
Static and serial assessments of coronary arterial remodeling are discordant: an intravascular ultrasound analysis from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am Heart J (2006) 1.48
Ongoing challenges for pharmacotherapy for dyslipidemia. Expert Opin Pharmacother (2014) 1.39
Clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound regression/progression studies. EuroIntervention (2011) 1.35
Intravascular imaging of vulnerable coronary plaque: current and future concepts. Nat Rev Cardiol (2011) 1.35
Sharing Data from Cardiovascular Clinical Trials - A Proposal. N Engl J Med (2016) 1.34
Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res (2012) 1.33
Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. J Lipid Res (2009) 1.31
Detection by near-infrared spectroscopy of large lipid core plaques at culprit sites in patients with acute ST-segment elevation myocardial infarction. JACC Cardiovasc Interv (2013) 1.21
Spotty calcification as a marker of accelerated progression of coronary atherosclerosis: insights from serial intravascular ultrasound. J Am Coll Cardiol (2012) 1.17
Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA (2007) 1.14
Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial. Circulation (2006) 1.14
Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo. Atherosclerosis (2007) 1.05
Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins. Atherosclerosis (2008) 1.03
Subclinical myocardial necrosis and cardiovascular risk in stable patients undergoing elective cardiac evaluation. Arterioscler Thromb Vasc Biol (2009) 1.02
Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res (2013) 1.00
Peripheral arterial disease and progression of coronary atherosclerosis. J Am Coll Cardiol (2011) 1.00
A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther (2013) 0.97
C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. Circulation (2013) 0.95
Factors underlying regression of coronary atheroma with potent statin therapy. Eur Heart J (2013) 0.94
Multiple risk factor intervention and progression of coronary atherosclerosis in patients with type 2 diabetes mellitus. Eur J Prev Cardiol (2012) 0.92
Coronary atherosclerosis can regress with very intensive statin therapy. Cleve Clin J Med (2006) 0.91
Brain natriuretic peptides as biomarkers for atherosclerosis. Prev Cardiol (2008) 0.90
Attenuated plaque at nonculprit lesions in patients enrolled in intravascular ultrasound atherosclerosis progression trials. JACC Cardiovasc Interv (2009) 0.89
The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins. Atherosclerosis (2011) 0.89
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opin Drug Saf (2015) 0.89
Exploring coronary atherosclerosis with intravascular imaging. Int J Cardiol (2013) 0.88
Biomarkers of inflammation and oxidative stress in atherosclerosis. Biomark Med (2010) 0.88
High-density lipoproteins: an emerging target in the prevention of cardiovascular disease. Cell Res (2006) 0.87
The emerging role of plasma lipidomics in cardiovascular drug discovery. Expert Opin Drug Discov (2011) 0.87
Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database. Eur J Prev Cardiol (2013) 0.87
Optimizing outcomes during left main percutaneous coronary intervention with intravascular ultrasound and fractional flow reserve: the current state of evidence. JACC Cardiovasc Interv (2012) 0.84
Cholesterol crystals associate with coronary plaque vulnerability in vivo. J Am Coll Cardiol (2015) 0.83
Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. Curr Med Res Opin (2013) 0.83
Compensatory enlargement of human coronary arteries during progression of atherosclerosis is unrelated to atheroma burden: serial intravascular ultrasound observations from the REVERSAL trial. Eur Heart J (2006) 0.83
Coronary β2-adrenoreceptors mediate endothelium-dependent vasoreactivity in humans: novel insights from an in vivo intravascular ultrasound study. Eur Heart J (2011) 0.82
Relationship of antihypertensive treatment to plasma markers of vascular inflammation and remodeling in the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis study. Am Heart J (2012) 0.82
Left main coronary atherosclerosis progression, constrictive remodeling, and clinical events. JACC Cardiovasc Interv (2013) 0.80
Coronary angiography for follow-up of heart transplant recipients: insights from TIMI frame count and TIMI myocardial perfusion grade. J Heart Lung Transplant (2007) 0.80
Treating stable ischemic heart disease with percutaneous coronary intervention - The debate continues. Cardiovasc Diagn Ther (2012) 0.80
The distinctive nature of atherosclerotic vascular disease in diabetes: pathophysiological and morphological insights. Curr Diab Rep (2012) 0.79
Intravascular ultrasound in the current percutaneous coronary intervention era. Cardiol Clin (2006) 0.79
Plaque progression in coronary arteries with minimal luminal obstruction in intravascular ultrasound atherosclerosis trials. Am J Cardiol (2010) 0.79
Progression of coronary atherosclerosis in African-American patients. Cardiovasc Diagn Ther (2013) 0.79
Paradoxical increase in lumen size during progression of coronary atherosclerosis: observations from the REVERSAL trial. Atherosclerosis (2006) 0.78
The complex intersection of inflammation and oxidation: implications for atheroprotection. J Am Coll Cardiol (2008) 0.78
Comparison of rates of progression of coronary atherosclerosis in patients with diabetes mellitus versus those with the metabolic syndrome. Am J Cardiol (2010) 0.78
Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥ 50% reduction in high-risk patients: results from VOYAGER. Atherosclerosis (2013) 0.77
Strategies for the development of new PPAR agonists in diabetes. Eur J Cardiovasc Prev Rehabil (2010) 0.77
Atherosclerotic plaque reduction: blood pressure, dyslipidemia, atherothrombosis. Drugs Today (Barc) (2008) 0.77
Favorable Impact on LDL Particle Size in Response to Treatment With Pioglitazone is Associated With Less Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes. J Am Coll Cardiol (2015) 0.77
Statins targeting inflammation by lowering low-density lipoprotein? J Am Coll Cardiol (2007) 0.77
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovasc Drugs Ther (2012) 0.77
The ASTEROID trial: coronary plaque regression with high-dose statin therapy. Future Cardiol (2006) 0.77
Coronary endothelium-dependent vasoreactivity and atheroma volume in subjects with stable, minimal angiographic disease versus non-ST-segment-elevation myocardial infarction: an intravascular ultrasound study. Circ Cardiovasc Imaging (2013) 0.77
Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy. Future Cardiol (2013) 0.76
Predicting the future: challenges moving forward for arterial imaging. Circulation (2012) 0.76
Statin-induced coronary artery disease regression rates differ in men and women. Curr Opin Lipidol (2015) 0.76
Coronary atheroma composition and its association with segmental endothelial dysfunction in non-ST segment elevation myocardial infarction: novel insights with radiofrequency (iMAP) intravascular ultrasonography. Int J Cardiovasc Imaging (2014) 0.75
Recent trends in coronary intravascular ultrasound: tracking atherosclerosis, pursuit of vulnerable plaques, and beyond. J Nucl Cardiol (2006) 0.75
Cellular Therapy for Heart Failure. Curr Cardiol Rev (2016) 0.75
Studying coronary plaque regression with IVUS. J Interv Cardiol (2006) 0.75
Insights from a virtual world. JACC Cardiovasc Interv (2011) 0.75
Lipid Lowering Therapy to Modify Plaque Microstructures. J Atheroscler Thromb (2017) 0.75
"Framing" the vessel: the critical importance of volumetric analysis during serial intravascular imaging studies. J Am Coll Cardiol (2012) 0.75
Aggressive treatment of high-density lipoprotein cholesterol. Ann Intern Med (2005) 0.75
Strategies to promote HDL-C: an emerging therapeutic target. Eur Heart J (2005) 0.75
Aortic atheroma burden predicts acute cerebrovascular events after transcatheter aortic valve implantation: insights from volumetric multislice computed tomography analysis. EuroIntervention (2016) 0.75
Clinical trials with cholesteryl ester transfer protein inhibitors. Curr Opin Lipidol (2016) 0.75
Coronary artery wall shear stress is associated with endothelial dysfunction and expansive arterial remodelling in patients with coronary artery disease. EuroIntervention (2015) 0.75
Rationale and approach to evaluation of the impact of medical therapies on progression of atherosclerosis with arterial wall imaging. Curr Med Res Opin (2010) 0.75
Suspected hypersensitivity reaction following drug-eluting stent implantation. Novel insights with optical coherence tomography. JACC Cardiovasc Interv (2012) 0.75
Reducing cardiovascular risk in patients with type 2 diabetes mellitus. Eur J Cardiovasc Prev Rehabil (2010) 0.75
Imaging of atherosclerotic plaques in obesity: excessive fat accumulation, plaque progression and vulnerability. Expert Rev Cardiovasc Ther (2014) 0.75
Statin effects on both low-density lipoproteins and high-density lipoproteins: is there a dual benefit? Curr Atheroscler Rep (2010) 0.75
Current imaging modalities for atherosclerosis. Expert Rev Cardiovasc Ther (2012) 0.75
Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. J Am Coll Cardiol (2016) 0.75
Controversies on HDL: should it be a target biomarker in patients with lipid disorders? Curr Vasc Pharmacol (2014) 0.75
Findings of clinical trials that evaluate the impact of medical therapies on progression of atherosclerosis. Curr Med Res Opin (2010) 0.75